RE: disgusting!13 Jan 2020 09:02
Absolutely! Am I missing something?
" We are very pleased with the tolerability of both oral and nasally administered Foralumab" added Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School, and study Principal Investigator ("PI"). "
"This Phase 1 trial, conducted at the Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, was a single-site, double-blind, placebo-controlled, single ascending dose ("SAD") study in healthy subjects in which Foralumab was orally administered at 1.25, 2.5 and 5.0 mg per dose as enteric-coated capsules. Each cohort comprised of 4 subjects, of whom 3 received Foralumab treatment and 1 received a placebo capsule. All subjects completed the trial without any safety concerns at any of the doses."
??? If they delist will they return? I could understand Motif Bio delisting from the NYSE as they dropped below the magic $1 min for the main market and didn't want to look shoddy (wolf of wall street lower market nightmare where no-one would invest again!) but here? All looking promising!